logo

Video encyclopedia

Samidorphan

1:04:52

Neurobiologic Insights into Major Depressive Disorder: Emerging Therapies with Novel MOAs

1:01:36

Dr. Roger S. McIntyre: Major Depressive Disorder and Bipolar Disorder

12:46

Just How Bad Is Alkermes' FDA Depression Drug Setback?

24:22

Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit from M&A

8:09

Alkermes Antidepressant Rejected by FDA | ALKS 5461

Samidorphan, also known as 3-carboxamido-4-hydroxynaltrexone, is an opioid antagonist that preferentially acts as an antagonist of the μ-opioid receptor (MOR). It is under development by Alkermes for the treatment of major depressive disorder and possibly other psychiatric conditions.
Explore contextually related video stories in a new eye-catching way. Try Combster now!